The Clinical Response to The Combination of Anlotinib and Tislelizumab in Multi-Line Treatment of a Metastasis Triple-Negative Breast Cancer Patient: A Case Report

1. Abstract
1.1. Background: We report a triple-negative breast cancer (TNBC) patient who progressed rapidly after multiple lines of conventional chemotherapy. However, this patient then responded well to the combination of anlotinib and immunotherapy.
1.2. Case Summary: A TNBC patient who underwent anthracycline and taxane-based and platinum-involved neoadjuvant treatment developed brain and lymph node metastases eight months after the modified radical mastectomy and the adjuvant capecitabine for eight cycles and olapali for one month. After receiving the whole-brain radiotherapy, the patient was treated with the first-line treatment of gemcitabine and carboplatin and second-line treatment of vinorelbine and oxaliplatin but still developed rapidly. However, this lady then responded well to the combination of anlotinib and tislelizumab. She achieved a partial response (PR) with a progression-free survival (PFS) of more than 13 months, followed by July 2021. This combination use was well tolerant and all the adverse reactions were under grade three, which mainly included hand-foot syndrome and myelosuppression.
1.3. Conclusion: The combination of anlotinib and tislelizumab is a good choice for metastasis triple-negative breast cancer (mTNBC) patients to achieve good clinical efficiency and well tolerance.